$Geron (GERN.US)$ Geron Says Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Recommended Approval Of RYTELO (Imetelstat) For Treatment Of Adult Patients With Transfusion-dependent (TD) Anemia Due To Very Low, Low Or Intermediate Risk Myelodysplastic Syndromes
Company says Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of RYTELO (imetelstat) for the treat...

Please take note of the following acronyms
NFA = not financial advice
RTH = regular trading hours
AH = after hours
LTB = left to borrow
CTB = cost to borrow
*I removed $AmpliTech Group (AMPG.US)$ because it just announced direct offering of $2M valued $1.6/shares.  Now there are offerings where market defies it and continues to rally. We shall see tomorrow
$Nuburu (BURU.US)$  PR AH 12/11: Resolved compliance issue. Up AH. Low float. CTB...

$U-BX Technology (UBXG.US)$ baggers

$Palisade Bio (PALI.US)$ it had all the indications that it was guaranteed according to my notes, rhetorical question, but, can anyone tell me what i'm doing wrong?

$Scorpius Holdings (SCPX.US)$ announcement of delist

$Geron (GERN.US)$ Reuters
3 mins ago
Geron Announces Phase 1 Findings From Two-Part Improvemf Study Presented at Ash Suggesting Tolerability of Rytelo™ (Imetelstat) in Combination With Ruxolitinib as Frontline Therapy in Patients With Myelofibrosis